Brokerages Set Krystal Biotech, Inc. (NASDAQ:KRYS) Target Price at $213.75

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) have received an average rating of "Buy" from the ten brokerages that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation, eight have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $211.33.

A number of analysts recently issued reports on the company. Citigroup reiterated a "neutral" rating and set a $176.00 price objective (up from $155.00) on shares of Krystal Biotech in a research note on Wednesday, July 9th. Bank of America reduced their target price on Krystal Biotech from $193.00 to $192.00 and set a "buy" rating for the company in a report on Tuesday. Guggenheim reduced their target price on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. HC Wainwright reaffirmed a "buy" rating and set a $240.00 target price on shares of Krystal Biotech in a report on Tuesday, June 24th. Finally, Chardan Capital restated a "buy" rating and issued a $219.00 target price on shares of Krystal Biotech in a research note on Wednesday, May 7th.

Insider Buying and Selling

In other news, insider Suma Krishnan sold 13,435 shares of the firm's stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $150.30, for a total value of $2,019,280.50. Following the completion of the sale, the insider directly owned 1,443,276 shares of the company's stock, valued at $216,924,382.80. This trade represents a 0.92% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders sold 49,800 shares of company stock worth $7,487,943 over the last three months. 13.70% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Krystal Biotech

Hedge funds and other institutional investors have recently modified their holdings of the business. Brooklyn Investment Group grew its stake in Krystal Biotech by 291.7% during the 1st quarter. Brooklyn Investment Group now owns 141 shares of the company's stock worth $25,000 after buying an additional 105 shares during the last quarter. Twin Tree Management LP purchased a new position in Krystal Biotech during the 1st quarter worth $29,000. Fifth Third Bancorp grew its stake in Krystal Biotech by 159.1% during the 1st quarter. Fifth Third Bancorp now owns 171 shares of the company's stock worth $31,000 after buying an additional 105 shares during the last quarter. Smartleaf Asset Management LLC grew its stake in Krystal Biotech by 128.3% during the 1st quarter. Smartleaf Asset Management LLC now owns 315 shares of the company's stock worth $58,000 after buying an additional 177 shares during the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S purchased a new position in Krystal Biotech during the 1st quarter worth $74,000. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Krystal Biotech Price Performance

Shares of KRYS stock traded up $1.35 during trading hours on Friday, reaching $153.25. The company had a trading volume of 265,393 shares, compared to its average volume of 286,525. Krystal Biotech has a 12 month low of $122.80 and a 12 month high of $219.34. The business has a fifty day simple moving average of $137.53 and a 200-day simple moving average of $155.81. The company has a market cap of $4.43 billion, a price-to-earnings ratio of 36.84 and a beta of 0.67.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported $1.20 earnings per share for the quarter, missing analysts' consensus estimates of $1.38 by ($0.18). The company had revenue of $88.18 million during the quarter, compared to the consensus estimate of $98.66 million. Krystal Biotech had a net margin of 37.17% and a return on equity of 14.64%. On average, equities research analysts expect that Krystal Biotech will post 6.14 earnings per share for the current year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).